Tesaro planning $165M note deal

Oncology play Tesaro Inc. (NASDAQ:TSRO) proposed late Monday to raise $165 million through the sale of senior unsecured convertible notes through Citigroup; Deutsche Bank Securities; Leerink; Baird; and BMO Capital Markets. The notes mature in October 2021.

The company plans to use the funds to commercialize oral rolapitant to prevent chemotherapy-induced nausea and vomiting (CINV), to develop intravenous rolapitant and other product candidates, and to finance potential in-licensing or product acquisition deals. ...